- |||||||||| Tyvyt (sintilimab) / Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
Review, Journal: Jejunal sarcomatoid carcinoma: A case report and review of literature. (Pubmed Central) - Aug 22, 2024
Patients without brain metastases had better clinical outcomes. This case suggests that chemotherapy, immunotherapy, plus targeted therapy may represent an optimal treatment for intestinal SCA, meriting further investigation.
- |||||||||| Tyvyt (sintilimab) / Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: Combination of Sintilimab and Anlotinib for Metastatic Osteosarcoma: A Case Report. (Pubmed Central) - Aug 20, 2024
The patient obtained an 11.7-month-sustained remission period, and he also enjoyed a better quality of life. This case demonstrates that sintilimab plus anlotinib may be a feasible treatment regimen for osteosarcoma patients.
- |||||||||| Journal, HEOR, Combination therapy, Cost-effectiveness, Cost effectiveness: Promising first-line immuno-combination therapies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis. (Pubmed Central) - Aug 16, 2024
NGS can provide SCLC patients with personalized and targeted therapy options, thereby improving their likelihood of survival. As one of the promising immuno-combination therapies in the first-line systemic treatment of HCC, camrelizumab plus rivoceranib demonstrated the potential to be the most cost-effective strategy, which warranted further studies to best inform the real-world clinical practices.
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Retrospective data, Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: The Efficiency and Safety of Triple-Drug Combination of Albumin-Bound Paclitaxel, Anlotinib and PD-1/L1 Inhibitors in the 2nd or Above Line of Advanced NSCLC: A Retrospective Cohort Study. (Pubmed Central) - Aug 13, 2024
Our study displayed that triple-drug combination of nab-ptx, anlotinib and PD-1/L1 inhibitors showed promising efficiency and tolerated cytotoxicity in the 2nd or above line treatment of advanced NSCLC, indicating the potential of such regimen as an important option for second-line treatment of advanced NSCLC. However, due to limitations in patient numbers, its actual clinical value awaits further research confirmation.
- |||||||||| AiTan (rivoceranib) / HLB Bio Group, Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal, Metastases: The Efficacy and Safety of Apatinib and Anlotinib in Advanced Non-Small Cell Lung Cancer. (Pubmed Central) - Aug 12, 2024
The incidence of grade 3-4 AEs was significantly higher in the apatinib group (31.65% vs 13.64%, P < 0.05). Anlotinib demonstrated greater efficacy and safety compared to apatinib in the treatment of advanced NSCLC, particularly in patients with bone metastases and EGFR(-).
- |||||||||| AiTan (rivoceranib) / HLB Bio Group
Retrospective data, Review, Journal: SEfficacy and safety of apatinib in the treatment of patients with platinum?resistant ovarian cancer: A systematic review and network meta?analysis. (Pubmed Central) - Aug 8, 2024
In addition, combinations of apatinib with etoposide (OR, 1.32; 95% CI, 1.06-1.64) or paclitaxel (OR, 1.52; 95% CI, 1.04-2.23) demonstrated a significantly improved disease control rates (DCR) compared with those following apatinib alone...In terms of safety, the incidence of adverse events, such as hand-foot syndrome [relative risk (RR), 4.23; 95% CI, 1.80-9.95] and hypertension (RR, 4.80; 95% CI, 1.53-15.05), was found to be significantly higher in patients treated with apatinib-containing therapies, compared with those treated with chemotherapy alone. Consequently, the present meta-analysis highlighted the potential of apatinib, particularly in combination with chemotherapy, as a therapeutic strategy for patients with platinum-resistant recurrent ovarian cancer.
- |||||||||| AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment closed, Phase classification, Trial primary completion date: Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma (clinicaltrials.gov) - Aug 7, 2024
P2/3, N=294, Active, not recruiting,
Consequently, the present meta-analysis highlighted the potential of apatinib, particularly in combination with chemotherapy, as a therapeutic strategy for patients with platinum-resistant recurrent ovarian cancer. Recruiting --> Active, not recruiting | Phase classification: PN/A --> P2/3 | Trial primary completion date: Mar 2024 --> Jul 2025
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Retrospective data, Journal, Real-world evidence, PD(L)-1 Biomarker, IO biomarker, Real-world, Metastases: Anlotinib reversed resistance to PD-1 inhibitors in recurrent and metastatic head and neck cancers: a real-world retrospective study. (Pubmed Central) - Aug 6, 2024
The most common grades 3-4 TRAE was hypertension (28.6%), and two treatment-related deaths occurred due to bleeding. Therefore, adding anlotinib to the original PD-1i could reverse PD-1 blockade resistance, with a favorable response rate, prolonged survival, and acceptable toxicity, indicating the potential as a second-line and subsequent therapy choice in R/M HNCs.
- |||||||||| brivudine (RP 101) / RESprotect, RedHill, SciClone, Focus V (anlotinib) / Advenchen, Sino Biopharm
disseminated herpes zoster in an immunocompromised patient (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_3868;
Next-generation sequencing techniques may offer improved diagnostic accuracy for drug- resistant viruses. Brivudine emerges as a potential therapeutic option for herpes zoster resistant to standard acyclovir therapy, although contraindications must be carefully considered.
- |||||||||| AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
P2 data, Journal, Combination therapy, Metastases: Efficacy and safety of camrelizumab, apatinib, and capecitabine combination therapy in advanced biliary tract cancer: a phase 2, nonrandomized, prospective study. (Pubmed Central) - Aug 5, 2024
P2
The adverse reactions of anlotinib are well tolerated and controllable. In this trial, the combination of camrelizumab, apatinib, and capecitabine showed promising antitumor activity and manageable toxicity in patients with advanced BTC, especially in the
- |||||||||| Irene (pyrotinib) / Jiangsu Hengrui Pharma, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: Treatment of HER2-Positive Breast Cancer with Brain Metastases Using Anlotinib and Trastuzumab Deruxtecan: A Case Report. (Pubmed Central) - Aug 5, 2024
The patient exhibited intracranial progression while receiving treatment with trastuzumab deruxtecan monotherapy after secondary brain radiotherapy and multiple lines of therapy with anti-HER2 agents, such as pyrotinib, lapatinib, tucatinib, and ado-trastuzumab emtansine...The present case indicates that the combination of anlotinib and trastuzumab deruxtecan may be a promising treatment option for patients with HER2+ breast cancer with brain metastasis. Nevertheless, further studies are warranted to verify the present findings.
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Review, Journal: Neuroendocrine carcinoma of the gallbladder: A case report and literature review. (Pubmed Central) - Aug 2, 2024
GB-NEC is associated with poor prognosis, emphasizing the importance of early detection and multimodal treatment strategies. Our case underlines the potential benefit of a comprehensive treatment plan, including aggressive surgery and chemotherapy, with further research needed to standardize treatment for this rare condition.
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: Frontline tyrosine kinase inhibitors in soft tissue sarcomas: a role for anlotinib? (Pubmed Central) - Aug 1, 2024
In this population, tyrosine kinase inhibitors (TKIs) represent an appealing alternative treatment strategy. First-line use of the TKI anlotinib in chemotherapy-ineligible soft tissue sarcoma patients showed promising activity across multiple histologies.
- |||||||||| sunvozertinib (DZD9008) / Dizal Pharma
SUCCESSFUL SUNVOZERTINIB RECHALLENGE FOR ADVANCED LUNG ADENOCARCINOMA WITH HER2 EXON20 INSERTION MUTATION: A CASE REPORT (Convention Center 257 AB) - Jul 31, 2024 - Abstract #CHEST2024CHEST_1858;
In December, he exhibited pronounced cough, sputum production, and dyspnea leading to self-administration of dacomitinib 45mg once daily plus anlotinib 12mg once daily orally (Figure 1D)... For NSCLC with HER2 exon20ins, sunvozertinib demonstrates efficacy in posterior-line therapy with tolerable adverse reactions, and remains effective upon re-challenge due to non-progressive factor.
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal, Metastases: Long-term survival in a patient with metastatic parathyroid carcinoma harboring an EGFR sensitizing mutation: a case report. (Pubmed Central) - Jul 27, 2024
After multidisciplinary treatment discussions, the patient was treated with the multi-target tyrosine kinase inhibitor, anlotinib, resulting in survival benefits for 19 months. This case highlights the potential of targeted therapy in terms of long-term survival in patients with distant metastatic PC, as well as the importance of precision therapy guided by genome sequencing to identify potential therapeutic targets.
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Anlotinib Mediated Inflammation Response Through NFKB/TNFRSF11A Cascade in Lung Cancer (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2493;
In vivo experiments confirmed a significant decrease in the expression of IL1B and TNFRSF11A in patient serum after Anlotinib treatment. Conclusions : The expression levels of immune-related genes IL1B and TNFRSF11A in the NFKB pathway have potential clinical applications and can be used to predict the response to Anlotinib.
- |||||||||| Clinical Outcomes of Continuous Immunotherapy Beyond Progression in Patients with Extensive-Stage Small Cell Lung Cancer (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2226;
Seventy-eight patients received PD-L1 antibody including atezolizumab, durvalumab, adebrelimab and envafolimab, while 19 patients received PD-1 antibody including pembrolizumab, serplulimab and tislelizumab...The second-line PFS of 23 patients receiving anti-angiogenic therapy such as anlotinib and sorafenib (14 in combination with immunotherapy or immunochemotherapy and 9 in combination with chemotherapy) was 5.3 months (95%CI: 3.5-7.1), indicating combined anti-angiogenic therapy may yield better survival benefit for ES-SCLC patients treated with first-line immunochemotherapy...Anti-angiogenic agent containing strategy may further improved survival after first-line immunochemotherapy. The long-term efficacy is still under follow-up.
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm, benmelstobart (APL-502) / Apollomics
Selection of Optimal Therapy for Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2221;
Conclusions : To the best of our knowledge, this NMA demonstrated for the first time that adding anlotinib and benmelstobart to chemotherapy significantly improved PFS and OS compared with chemotherapy alone or chemotherapy plus immunotherapy, with an acceptable safety profile in patients with ES-SCLC. In conclusion, Anl/Ben/CT could be a new and clinically preferable first-line treatment option for this population.
- |||||||||| Orpathys (savolitinib) / AstraZeneca, Hutchmed
Durable Response to Savolitinib in Advanced EGFR-WT NSCLC with MET Amplification: Case Series (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2154;
Further data from larger cohorts and longer follow-up are needed to confirm these findings. Table: Case series chart of four patients Patient case Sex Age Smoking History T NM stage Metastases MET CN IHC Concurrent mutation Prior treatment Regimen Response Adverse events 1 Male 52 Yes cT4N3M1c Bones, adrenal gland 14 M ET IHC 3+ (90%) , PD-L 1 positive ( TPS:60% + ) TP53 mutation None Savolitinib monotherapy PR, ongoing None reported 2 Male 75 Yes cT1cN0M1c Bone 17.1 M ET IHC 2+ (100%) , PD-L1 positive ( TPS:80%+) TP53 mutation; ARID1A mutation; KMT2D mutation; RICTOR amplification; RICTOR mutation None Savolitinib monotherapy PR, ongoing None reported 3 Female 67 No cT4N3M1c Brain 1.6(1 st -line )4.1 (re-biopsy) Re-biopsy: M ET IHC 3+ (100%) , PD-L1 positive (TPS:45%+) NTRK fusion; TP53 mutation; PIK3CA mutation; FGFR1 a mplication; ATM mutation; RICTOR mutation; Entrectinib Savolitinib with Anlotinib PR , ongoing None reported 4 Male 67 Yes cT2N3M1c Thoracic vertebral, brain 3.3 PD-L1 ( TPS : 85% ) TP53 mutation; BRCA2 mutation; NF2 mutation; Combined immunochemotherapy Savolitinib, with sindilimab PR , ongoing Interstitial pneumonia
- |||||||||| What is the Optimal First-Line Regimen for EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Network Meta-Analysis (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2118;
Compared with other interventions, combination therapies based on third-generation TKIs, especially osimertinib plus ramucirumab (OSI_RAM), showed the most favorable PFS prolongation in overall patients (Figure A)...In terms of overall survival, despite the combination regimens based on third-generation TKIs also showing relatively superior outcomes, erlotinib plus chemotherapy and gefitinib plus chemotherapy were ranked more favorably (Figure B)...Conclusions : Combination regimens based on third-generation TKIs, especially OSI_RAM, showed superior efficacy compared with third-generation TKIs monotherapy or other regimens as first-line therapy in EGFR-mutated advanced NSCLC, along with an acceptable safety profile. Our study concluded that combination regimens based on third-generation TKIs (OSI_RAM, OSI plus chemotherapy, OSI plus bevacizumab, amivantamab plus lazertinib and aumolertinib plus apatinib) could be the new and clinically preferable first-line, standard of care for EGFR-mutated advanced NSCLC.
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Anlotinib Combined with Immune Checkpoint Inhibitor May Benifit Advanced Smarca4-Deficient Thoracic Tumor Patients in First Line (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_2104;
Overall survival(OS) was significantly longer in patients who received first-line immnotherapy compared to those who receive first-line immunotherapy or no immunotherapy(21.67m vs. 8.80m, p=0.027)(Figure2). Conclusions : SMARCA4-deficient thoracic tumor has unique clinicopathologic features and worse prognosis, and immue checkpoint inhibitors combined with anlotinib may be a better treatment for first-line.
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Efficacy and Safety of Anlotinib Plus EGFR-TKIs in Slowly or Locally Progressing NSCLC after Adjuvant Therapy with EGFR-TKIs (Exhibit Hall) - Jul 24, 2024 - Abstract #IASLCWCLC2024IASLC_WCLC_1965;
Dose reduction and discontinuation of anlotinib were reported in 4 (8.3%) and 5 (10.4%) patients, respectively. Conclusions : For patients with NSCLC who experienced slow or local progression after postoperative adjuvant therapy with EGFR-TKIs, anlotinib in combination with EGFR-TKIs showed promising efficacy and manageable safety, providing such patients with a longer treatment window and survival opportunity.
|
